1. FDA Committee Votes 6-6 on Durect's Non-Opioid Pain Drug — Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 — Novo Nordisk's Ozempic wins FDA label boost with CV indication — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Revenue growth

Discussion in 'Quest Diagnostics' started by anonymous, Oct 26, 2019 at 11:46 AM.

  1. anonymous

    anonymous Guest

    How can this company increase revenue in this environment?

    Any ideas?
     
  2. anonymous

    anonymous Guest

    By taking all the halfwits, such as yourself, and immediately terminating their employment for cause. What cause, you ask? Criminal stupidity. Hope this helps.
     
  3. anonymous

    anonymous Guest


    Mean and uncalled for. I only hope that your negative Karma comes back and haunts you.

    You’re a meanie, rude person.
     
  4. anonymous

    anonymous Guest

    Package and sell the data. It is a gold mine if done strategically.